Sekeres MA - Search Results

1

Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

Ai J, Visconte V, Tabarroki A, Hasrouni E, Hamilton BK, Mukherjee S, Kalaycio M, Sobecks R, Advani AS, Sekeres MA, Shetty S, Tiu RV. Ai J, et al. Among authors: sekeres ma. Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):489-95. doi: 10.1016/j.clml.2015.03.017. Epub 2015 Apr 2. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25977195

2

Alternative treatments for myelodysplastic syndromes.

Sekeres M, List A. Sekeres M, et al. Semin Hematol. 2005 Jul;42(3 Suppl 2):S32-7. doi: 10.1053/j.seminhematol.2005.05.008. Semin Hematol. 2005. PMID: 16015503 Review.

3

The role of post-remission chemotherapy for older patients with acute myelogenous leukemia.

Abou-Jawde RM, Sobecks R, Pohlman B, Rybicki L, Advani A, Sekeres M, Kalaycio M. Abou-Jawde RM, et al. Leuk Lymphoma. 2006 Apr;47(4):689-95. doi: 10.1080/10428190500353554. Leuk Lymphoma. 2006. PMID: 16690528

4

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP. Szpurka H, et al. Among authors: sekeres ma. Blood. 2006 Oct 1;108(7):2173-81. doi: 10.1182/blood-2006-02-005751. Epub 2006 Jun 1. Blood. 2006. PMID: 16741247 Free PMC article.

5

Immunomodulation in myelodysplastic syndromes.

Sekeres MA, List A. Sekeres MA, et al. Best Pract Res Clin Haematol. 2006;19(4):757-67. doi: 10.1016/j.beha.2006.06.001. Best Pract Res Clin Haematol. 2006. PMID: 16997181 Review.

6

High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes.

O'Keefe CL, Tiu R, Gondek LP, Powers J, Theil KS, Kalaycio M, Lichtin A, Sekeres MA, Maciejewski JP. O'Keefe CL, et al. Among authors: sekeres ma. Exp Hematol. 2007 Feb;35(2):240-51. doi: 10.1016/j.exphem.2006.09.016. Exp Hematol. 2007. PMID: 17258073 Free PMC article.

7

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.

Sekeres MA, Fu AZ, Maciejewski JP, Golshayan AR, Kalaycio ME, Kattan MW. Sekeres MA, et al. Cancer. 2007 Mar 15;109(6):1125-32. doi: 10.1002/cncr.22497. Cancer. 2007. PMID: 17265521 Free article.

8

The myelodysplastic syndromes.

Sekeres MA. Sekeres MA. Expert Opin Biol Ther. 2007 Mar;7(3):369-77. doi: 10.1517/14712598.7.3.369. Expert Opin Biol Ther. 2007. PMID: 17309328 Review.

9

The incidence and impact of thrombocytopenia in myelodysplastic syndromes.

Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R, Leveque J. Kantarjian H, et al. Among authors: sekeres ma. Cancer. 2007 May 1;109(9):1705-14. doi: 10.1002/cncr.22602. Cancer. 2007. PMID: 17366593 Free article. Review.

10

Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.

Golshayan AR, Jin T, Maciejewski J, Fu AZ, Bershadsky B, Kattan MW, Kalaycio ME, Sekeres MA. Golshayan AR, et al. Among authors: sekeres ma. Br J Haematol. 2007 Apr;137(2):125-32. doi: 10.1111/j.1365-2141.2007.06546.x. Br J Haematol. 2007. PMID: 17391492 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

424 results

Search Page